Key result
The custom-designed gene-targeted CGH array successfully identified pathogenic deletions and duplications in 36 of 99 clinical samples, proving to be a robust platform for routine diagnostic dosage analysis.
Observational (n=99)
No
A custom-designed CGH array provides a robust and flexible platform for gene dosage analysis in small diagnostic laboratories.
May enable routine dosage analysis in small labs; leaves open prospective validation before wider cardiovascular adoption.
The role of gene deletion and duplication in the aetiology of disease has become increasingly evident over the last decade. In addition to the classical deletion/duplication disorders diagnosed using molecular techniques, such as Duchenne Muscular Dystrophy and Charcot-Marie-Tooth Neuropathy Type 1A, the significance of partial or whole gene deletions in the pathogenesis of a large number single-gene disorders is becoming more apparent. A variety of dosage analysis methods are available to the diagnostic laboratory but the widespread application of many of these techniques is limited by the expense of the kits/reagents and restrictive targeting to a particular gene or portion of a gene. These limitations are particularly important in the context of a small diagnostic laboratory with modest sample throughput. We have developed a gene-targeted, custom-designed comparative genomic hybridisation (CGH) array that allows twelve clinical samples to be interrogated simultaneously for exonic deletions/duplications within any gene (or panel of genes) on the array. We report here on the use of the array in the analysis of a series of clinical samples processed by our laboratory over a twelve-month period. The array has proven itself to be robust, flexible and highly suited to the diagnostic environment.
No takes yet. Share an insight, caveat, or question.
Marquis‐Nicholson et al. (2013) conducted an observational in Single-gene disorders (e.g., DMD, CMT1A, Cowden syndrome) (n=99). Gene-targeted comparative genomic hybridisation (CGH) array was evaluated on Detection of pathogenic gene deletions and duplications. The custom-designed gene-targeted CGH array successfully identified pathogenic deletions and duplications in 36 of 99 clinical samples, proving to be a robust platform for routine diagnostic dosage analysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: